CHMA - Chiasma Trades At A Big Discount To Fair Value With Mycapssa On The Market
- Chiasma launched its first product, Mycapssa, on August 31, 2020.
- Mycapssa is the first product utilizing Chiasma's proprietary technology platform that enables oral version of previously injection-only therapies by transiently enhancing intestinal permeability.
- Chiasma is well-funded for this launch with over $175 million in cash and equivalents in the bank, likely enough to last through mid-2022.
- Chiasma trades for less than probable Mycapssa peak sales which leaves a lot of potential upside from present levels.
For further details see:
Chiasma Trades At A Big Discount To Fair Value With Mycapssa On The Market